Skip to content
Subscriber Only

CureVac Covid Vaccine Shows Immune Response in Early Trial

  • Early tests show experimental shot yielded antibodies, T cells
  • Vaccine could be company’s first-ever licensed product
The CureVac NV coronavirus vaccine.

The CureVac NV coronavirus vaccine.

Source: CureVac

Updated on

A coronavirus vaccine under development from CureVac NV showed a good immune response in early trials, validating the biotech company’s 20 years of research into messenger RNA’s ability to train the body’s defenses.

The vaccine’s strongest dose produced an immune response comparable to that found in recovered patients in an early-stage test on more than 250 volunteers, the German company said in a statement Monday. Chief Executive Officer Franz-Werner Haas said advanced clinical trials are on track to start by year-end. CureVac shares rose as much as 5% in Frankfurt trading.